Clinical trial
A Randomized, Double-blind, Placebo-controlled Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Multiple Doses AK0529 in Adult Hospitalized Subjects With Respiratory Syncytial Virus Infection
NCT06942299 is registered in ClinicalTrials.gov with Shanghai Ark Biopharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Multiple Doses AK0529 in Adult Hospitalized Subjects With Respiratory Syncytial Virus Infection
- Lead sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 20, 2023
- Completion date
- June 28, 2024
- Enrollment
- 25 (actual)
- Sites
- 42
Conditions
As the registry lists them; a condition with its own page is linked.